Cargando…

A Review of Randomized Controlled Trials of Hereditary Angioedema Long-Term Prophylaxis with C1 Inhibitor Replacement Therapy: Alleviation of Disease Symptoms Is Achievable

Through its fluctuating disease activity and unpredictable attacks, hereditary angioedema (HAE) imposes a substantial patient burden. To minimize HAE burden and improve quality of life, treatment should involve individualized management strategies that address on-demand therapy and short-term/long-t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Longhurst, Hilary J, Valerieva, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010185/ https://www.ncbi.nlm.nih.gov/pubmed/36922963 http://dx.doi.org/10.2147/JAA.S396338

Ejemplares similares

Treatment of hereditary angioedema—single or multiple pathways to the rescue
por: Valerieva, Anna, et al.
Publicado: (2022)

Long-term prophylaxis of hereditary angioedema with danazol
por: Xu, Yingyang, et al.
Publicado: (2022)

Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey
por: Aberer, Werner, et al.
Publicado: (2017)

Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe
por: Zanichelli, Andrea, et al.
Publicado: (2013)

Management of acute attacks of hereditary angioedema: potential role of icatibant
por: Longhurst, Hilary J
Publicado: (2010)

Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab
por: Wong, Jane C.Y., et al.
Publicado: (2023)

Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus
por: Longhurst, Hilary
Publicado: (2018)

Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema
por: Craig, Timothy, et al.
Publicado: (2017)

Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries
por: Guo, Yinshi, et al.
Publicado: (2022)

Therapeutic management of hereditary angioedema: past, present, and future
por: Valerieva, Anna, et al.
Publicado: (2021)

Successful C1 inhibitor short-term prophylaxis during redo mitral valve replacement in a patient with hereditary angioedema
por: Bernstein, Jonathan A, et al.
Publicado: (2010)

A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema
por: Aygören‐Pürsün, Emel, et al.
Publicado: (2019)

Hereditary Angioedema with Normal C1 Esterase Inhibitor Refractory to Long-Term Prophylaxis: A Case Report
por: Cobb, Gavin, et al.
Publicado: (2023)

Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema
por: Jindal, Ankur Kumar, et al.
Publicado: (2021)

Short-term Prophylaxis for Delivery in Pregnant Women with Hereditary Angioedema with Normal C1-Inhibitor
por: Moraes, Caroline Guth de Freitas Batista de, et al.
Publicado: (2020)

Informed decision‐making in hereditary angioedema prophylaxis
por: Burnette, Autumn Ford
Publicado: (2021)

Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy
por: Lumry, William, et al.
Publicado: (2020)

Editorial: C1 inhibitor deficiency and angioedema
por: Farkas, Henriette, et al.
Publicado: (2022)

The physician and hereditary angioedema friend or foe: 62-year diagnostic delay and iatrogenic procedures
por: Valerieva, Anna, et al.
Publicado: (2018)

WAO Guideline for the Management of Hereditary Angioedema
por: Craig, Timothy, et al.
Publicado: (2012)

Case report: follow-up of long term prophylaxis of hereditary angioedema with an alternative attenuated androgenic drug
por: Tebyrica, João
Publicado: (2015)

Safety Aspects and Rational Use of Lanadelumab Injections in the Treatment of Hereditary Angioedema (HAE): Clinical Insights
por: Petkova, Elena, et al.
Publicado: (2022)

Correction to: Mitigating Disparity in Healthcare Resources Between Countries for Management of Hereditary Angioedema
por: Jindal, Ankur Kumar, et al.
Publicado: (2021)

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate
por: Zuraw, B. L., et al.
Publicado: (2015)

Canadian hereditary angioedema guideline
por: Betschel, Stephen, et al.
Publicado: (2014)

Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy
por: Bova, Maria, et al.
Publicado: (2019)

Recombinant human C1 esterase inhibitor for hereditary angioedema attacks: A European registry()
por: Valerieva, Anna, et al.
Publicado: (2021)

C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option
por: Longhurst, H J, et al.
Publicado: (2007)

Reviewing clinical considerations and guideline recommendations of C1 inhibitor prophylaxis for hereditary angioedema
por: Anderson, John, et al.
Publicado: (2022)

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020)

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies
por: Busse, Paula J., et al.
Publicado: (2018)

Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema
por: Levy, Donald, et al.
Publicado: (2020)

Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema
por: Zhang, Ying, et al.
Publicado: (2018)

Real-Life Experience With Subcutaneous Plasma-Derived C1-Inhibitor for Long-Term Prophylaxis in Patients With Hereditary Angioedema: A Case Series
por: Zanichelli, Andrea, et al.
Publicado: (2022)

Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
por: Lumry, William R., et al.
Publicado: (2021)

Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study
por: Riedl, M. A., et al.
Publicado: (2018)

Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment
por: Maurer, Marcus, et al.
Publicado: (2013)

An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
por: Riedl, Marc A., et al.
Publicado: (2017)

Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
por: Lumry, William R., et al.
Publicado: (2021)

Hereditary angioedema
por: Lesser, Helen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r1gks7udgnfdi6rf6m627np707